68 related articles for article (PubMed ID: 35834427)
1. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
[TBL] [Abstract][Full Text] [Related]
2. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
[TBL] [Abstract][Full Text] [Related]
3. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
4. MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma.
Kendall J; Hall A; Roberts S; Brown S; Boyd K; Auner HW; Garg M; Kaiser M
BMJ Open; 2022 Oct; 12(10):e062504. PubMed ID: 36288835
[TBL] [Abstract][Full Text] [Related]
5. Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study.
Jagannath S; Delimpasi S; Grosicki S; Van Domelen DR; Bentur OS; Špička I; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):917-923.e3. PubMed ID: 37743180
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
[TBL] [Abstract][Full Text] [Related]
7. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D; Berdeja JG; Reece D; White D; Lentzsch S; Gasparetto C; Huff CA; Jagannath S; Baz R; Nooka AK; Richter J; Abonour R; Parker TL; Yee AJ; Moreau P; Lonial S; Tuchman S; Weisel KC; Mohty M; Choquet S; Unger TJ; Li K; Chai Y; Li L; Shah J; Shacham S; Kauffman MG; Dimopoulos MA
Leukemia; 2020 Sep; 34(9):2430-2440. PubMed ID: 32094461
[TBL] [Abstract][Full Text] [Related]
8. Selinexor in multiple myeloma.
Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
[TBL] [Abstract][Full Text] [Related]
9. US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma.
Dolph M; Tremblay G; Leong H
Clinicoecon Outcomes Res; 2021; 13():493-502. PubMed ID: 34140789
[TBL] [Abstract][Full Text] [Related]
10. Treatment of multiple myeloma with selinexor: a review.
Huang Q; Zhao R; Xu L; Hao X; Tao S
Ther Adv Hematol; 2024; 15():20406207231219442. PubMed ID: 38186637
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis.
Shafei L; Bashir S; Chan EW; Abushanab D; Hamad A; Al-Badriyeh D
Curr Probl Cancer; 2024 Mar; 50():101076. PubMed ID: 38537395
[TBL] [Abstract][Full Text] [Related]
12. Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor.
Gordan LN; Ray D; Ijioma SC; Dranitsaris G; Warner A; Heritage T; Fink M; Wenk D; Chadwick P; Khrystolubova N; Peles S
Curr Oncol; 2024 Jan; 31(1):501-510. PubMed ID: 38248119
[TBL] [Abstract][Full Text] [Related]
13. The development and validation of a liquid chromatography tandem mass spectrometry method for the quantification of selinexor and its application in Chinese multiple myeloma patients.
Yan X; He X; Yang X; Zhao Q; Lou Y
Anal Methods; 2024 Feb; 16(7):1050-1057. PubMed ID: 38269419
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis.
Yi JH; Park SS; Min CK; Eom HS; Byun JM; Koh Y; Yoon SS; Lee JH; Jung SH; Lee JJ; Yoon SE; Woo SY; Kim K
Ann Hematol; 2024 Jan; ():. PubMed ID: 38267559
[TBL] [Abstract][Full Text] [Related]
15. Selinexor for Refractory Multiple Myeloma.
Jhaveri KD; Wanchoo R
N Engl J Med; 2019 Nov; 381(20):1977. PubMed ID: 31722162
[No Abstract] [Full Text] [Related]
16. Selinexor for Refractory Multiple Myeloma. Reply.
Chari A; Vogl DT; Jagannath S
N Engl J Med; 2019 Nov; 381(20):1977-1978. PubMed ID: 31722163
[No Abstract] [Full Text] [Related]
17. Selinexor: Targeting a novel pathway in multiple myeloma.
Mo CC; Yee AJ; Midha S; Hartley-Brown MA; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
EJHaem; 2023 Aug; 4(3):792-810. PubMed ID: 37601856
[TBL] [Abstract][Full Text] [Related]
18. Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
Remaggi G; Ochoa PA; Garate GM
Am J Case Rep; 2022 Jul; 23():e936505. PubMed ID: 35834427
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
